Physician profile
Mark Schlotterback
NPI 1861449944
$9,155.20
in general payments reported to CMS, 2019-2025
58 companies · $2,105 in 2025
The $2,105 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,736 · 2020: $623 · 2021: $150 · 2022: $1,449 · 2023: $1,511 · 2024: $1,581 · 2025: $2,105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,172 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,171.85 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,271.69 | 2022-2025 | Qulipta, Vraylar, Synthroid |
| Astrazeneca Pharmaceuticals LP | $940.33 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $718.15 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $602.67 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $592.31 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $566.03 | 2019-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $539.94 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $388.91 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $304.06 | 2019-2025 | Gardasil 9, Capvaxive, M-M-R II |
| Teva Pharmaceuticals USA, INC. | $192.74 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $189.67 | 2019-2025 | |
| Abbott Laboratories | $180.50 | 2019-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $179.05 | 2019-2025 | Veozah |
| Allergan, INC. | $174.93 | 2019-2020 | |
| Dexcom, INC. | $170.86 | 2023-2025 | Dexcom G6 Transmitter |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Schlotterback listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.